Analysis of the Efficacy and Security of Camrelizumab Combined with Lenvatinib in the Treatment of Advanced Liver Cancer
Objective To explore the efficacy of camrelizumab combined with lenvatinib in the treatment of advanced liver cancer patients.Methods A retrospective analysis was conducted on the clinical data of 86 patients with advanced liver cancer who received treatment in our hospital from January 2020 to January 2023.According to different treatment plans,the data of 43 patients receiving lenvatinib treatment were divided into a control group,and the data of 43 patients receiving camrelizumab combined with lenvatinib treatment were divided into an observation group.The therapeutic efficacy,biochemical indicators,and safety of the two groups were compared.Results The disease control rate of the observation group was 72.09%,higher than 48.84%of the control group,and the difference was statistically significant(P＜0.05).After three courses of treatment,the levels of alpha-fetoprotein(AFP),abnormal prothrombin(APT)in the observation group were lower than those in the control group,and the differences between the groups were statistically significant(P＜0.05).There was no statistically significant difference in the incidence of hand foot syndrome,fatigue,rash,diarrhea,decreased appetite,elevated bilirubin,acute kidney injury,hypothyroidism,liver dysfunction,and thrombocytopenia between the two groups(P＞0.05).Conclusion The combination of camrelizumab and lenvatinib in the treatment of advanced liver cancer patients has a significant effect,can effectively improve AFP and APT levels,and has a certain security.
NETL
NSTL
万方数据
